ERBB2 and urothelial carcinoma: Preliminary data about disitamab vedotin combined with toripalimab displayed a satisfactory clinical benefit, with ORR of 100% in Her-2 (3+), 77.8% in Her-2 (2+), 66.7% in Her-2 (1+), and 50% in HER2 negative patients with urothelial carcinoma, respectively (26).